Cohort B will investigate CA-4948 in combination with FOLFOX/pembrolizumab and trastuzumab. The initial 6 patients in Cohort B will be considered safety lead-in to confirm the safety and tolerability at the RP2D, followed by additional patients, up to 12 patients treated at the RP2D. The ...
Firstline pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21:821–831.2.Rha SY, Lee CK, Kim HS, Kang B, Jung M, Kwon WS, et al. A multi-institutional phase Ib/II...
3541 Background: Pembrolizumab (PEM) has activity in patients with deficient mismatch repair (dMMR) colorectal cancer (CRC). Oxaliplatin (OX) and 5FU lead to immunogenic cell death and increased antigen presentation. We hypothesized that combining mFOLFOX6 and PEM may enhance immunogenic cell death...
Int J Cancer. 2023;152:749–60. https://doi.org/10.1002/ijc.34296. Article CAS PubMed Google Scholar Oh D-Y, Bai Y, Ryu MH, et al. 138MO pembrolizumab (pembro) or placebo (Pbo) plus chemotherapy (Chemo) for advanced HER2-negative gastric/gastroesophageal junction (G/GEJ) ...
24-Month Overall Survival from KEYNOTE-021 Cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsqua mous non-small cell lung cancer. J Thorac Oncol. 2019;14 (1):124–129. doi:10.1016/j.jtho.2018.08.004 26. Paz-Ares L, Luft A, ...
鉴于这一研究成果的公布, 2021年美国综合肿瘤网络(National Comprehensive Cancer Network, NCCN)指南及中国临床肿瘤学会(Chinese Society of Clinical Oncology, CSCO)指南均将纳武利尤单抗+化疗(FOLFOX/XELOX)方案正式列为晚期转移性胃癌一线...
Conclusions: The perioperative pembrolizumab and mFOLFOX combination in resectable esophageal/gastric/GEJ adenocarcinoma is very effective with 90% ypRR, 21% ypCR, and impressive long‐time survival benefits.Sun, WeijingVeeramachaneni, NirmalAl‐Rajabi, Raed...
Int J Cancer. 2023;152:749–60. https://doi.org/10.1002/ijc.34296. 19. Oh D-Y, Bai Y, Ryu MH, et al. 138MO pembrolizumab (pem- bro) or placebo (Pbo) plus chemotherapy (Chemo) for advanced HER2-negative gastric/gastroesophageal junction (G/GEJ) adeno- ...
A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer 3541 Background: Pembrolizumab (PEM) has activity in patients with deficient mismatch repair (dMMR) colorectal cancer (CRC). Oxaliplatin (OX) and 5FU lead to immunogenic cell death and inc...
24-Month Overall Survival from KEYNOTE-021 Cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsqua mous non-small cell lung cancer. J Thorac Oncol. 2019;14 (1):124–129. doi:10.1016/j.jtho.2018.08.004 26. Paz-Ares L, Luft A, ...